CY1123989T1 - Συνθεση αντηλιακου - Google Patents

Συνθεση αντηλιακου

Info

Publication number
CY1123989T1
CY1123989T1 CY20211100183T CY211100183T CY1123989T1 CY 1123989 T1 CY1123989 T1 CY 1123989T1 CY 20211100183 T CY20211100183 T CY 20211100183T CY 211100183 T CY211100183 T CY 211100183T CY 1123989 T1 CY1123989 T1 CY 1123989T1
Authority
CY
Cyprus
Prior art keywords
vitamin
porphyrin
analogs
sunscreen composition
sunscreen
Prior art date
Application number
CY20211100183T
Other languages
English (en)
Inventor
Ana SOLER
Trond Warloe
Qian Peng
Original Assignee
3Skin As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3Skin As filed Critical 3Skin As
Publication of CY1123989T1 publication Critical patent/CY1123989T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Αποκαλύπτεται βελτιωμένη διαδερματική σύνθεση αντηλιακού που συμπεριλαμβάνει πορφυρίνη, ανάλογα πορφυρίνης ή/και προδρόμους πορφυρίνης (ιδιαιτέρως 5-αμινολεβουλινικό οξύ, ALA) σε μία υποθεραπευτική δόση σε συνδυασμό με βιταμίνη D3 ή ανάλογα/παράγωγα αυτής σε ένα διαδερματικό φορέα ή σύστημα φορέα για να δημιουργήσει βιοϊατρικά αποτελέσματα επί της μείωσης καταστάσεων φωτο-βλαφθέντος δέρματος, διέγερσης αναγέννησης δέρματος και εξισορρόπησης βιταμίνης D3 για προκαλούμενη από αντηλιακό μείωση/ανεπάρκεια βιταμίνης D3, ενώ ταυτοχρόνως αναστέλλει επιβλαβή UV ακτινοβολία από το να φτάσει και να βλάψει το DNA στα κύτταρα του δέρματος.
CY20211100183T 2017-02-06 2021-03-03 Συνθεση αντηλιακου CY1123989T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20170179 2017-02-06
PCT/EP2018/052949 WO2018141988A1 (en) 2017-02-06 2018-02-06 Sunscreen composition

Publications (1)

Publication Number Publication Date
CY1123989T1 true CY1123989T1 (el) 2022-05-27

Family

ID=61189448

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100183T CY1123989T1 (el) 2017-02-06 2021-03-03 Συνθεση αντηλιακου

Country Status (15)

Country Link
US (2) US20200100997A1 (el)
EP (2) EP3725374B1 (el)
KR (1) KR20190112096A (el)
CN (1) CN110325246B (el)
AU (1) AU2018216043B2 (el)
BR (1) BR112019015568B1 (el)
CA (1) CA3051727A1 (el)
CY (1) CY1123989T1 (el)
DK (1) DK3576846T3 (el)
ES (2) ES2981753T3 (el)
HR (1) HRP20210323T1 (el)
HU (1) HUE053510T2 (el)
PL (1) PL3576846T3 (el)
PT (1) PT3576846T (el)
WO (1) WO2018141988A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3362145B1 (en) 2015-10-15 2021-01-06 DUSA Pharmaceuticals, Inc. Adjustable illuminator for photodynamic therapy and diagnosis
US10603508B2 (en) 2015-10-15 2020-03-31 Dusa Pharmaceuticals, Inc. Adjustable illuminators and methods for photodynamic therapy and diagnosis
US10357567B1 (en) 2018-01-12 2019-07-23 Dusa Pharmaceuticals, Inc. Methods for photodynamic therapy
US11756685B2 (en) * 2020-06-23 2023-09-12 L'oreal Ultraviolet light sensor and method to achieve targeted vitamin D levels
ES2956376A1 (es) * 2022-05-13 2023-12-20 Espada Regalado Jesus Uso de un procedimiento de transferencia fotonica secuencial para fomentar la fotoproteccion y regeneracion cutanea

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002845A1 (en) * 1983-01-21 1984-08-02 Advanced Drug Tech Vitamin-containing skin care ointment
US4610978A (en) * 1983-03-22 1986-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same
US5079262A (en) 1989-07-28 1992-01-07 Queen's University At Kingston Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
DE4320871C2 (de) 1993-06-24 1995-05-04 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen mit einem Gehalt an delta-Aminolävulinsäure
WO1996028412A1 (en) 1995-03-10 1996-09-19 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
NO20002428D0 (no) * 2000-05-10 2000-05-10 Radiumhospitalets Forskningsst Hudpreparat
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
EP2269645A3 (en) * 2000-08-16 2011-01-12 The General Hospital Corporation doing business as Massachusetts General Hospital Topical aminolevulinic acid-photodynamic therapy for acne vulgaris
JP2004175731A (ja) * 2002-11-28 2004-06-24 Noevir Co Ltd 老化防止用皮膚外用剤
US20050209331A1 (en) * 2004-03-22 2005-09-22 Syneron Medical Ltd. Method of treatment of skin
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
WO2006039281A2 (en) * 2004-09-29 2006-04-13 Person John R Skin cancer prevention method and product
US20090130227A1 (en) * 2005-04-28 2009-05-21 Yoshiyasu Ito External preparation for skin
US8034788B2 (en) * 2005-05-10 2011-10-11 Dermipsor Ltd. Composition and methods for skin care
WO2008106966A1 (en) * 2007-03-06 2008-09-12 Christiansen Kaare A method for non-therapeutic or therapeutic photodynamic skin treatment
WO2011107478A1 (en) * 2010-03-01 2011-09-09 Photocure Asa Cosmetic compositions
WO2013092936A2 (en) * 2011-12-20 2013-06-27 Galderma Research & Development Use of 5-aminolevulinic acid and esters, in combination with a vitamin d derivative or analog in photochemotherapy, and their uses in treating acne
BR112016014073A2 (pt) * 2013-12-20 2017-08-08 Galderma Res & Dev Tratamento fotodinâmico de pulso de pele fotodanificada
EP3939593A1 (en) * 2014-09-10 2022-01-19 Washington University Compositions and methods for treatment of pre-cancerous skin lesions
KR20160141297A (ko) * 2015-05-29 2016-12-08 (주)클레어스코리아 피부 탄력에 효과를 갖는 마유를 함유하는 피부 재생용 화장료 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
EP3576846A1 (en) 2019-12-11
DK3576846T3 (da) 2021-03-01
AU2018216043B2 (en) 2020-02-27
EP3725374A1 (en) 2020-10-21
EP3725374C0 (en) 2024-06-19
US20220313580A1 (en) 2022-10-06
PL3576846T3 (pl) 2021-07-19
KR20190112096A (ko) 2019-10-02
CA3051727A1 (en) 2018-08-09
ES2859777T3 (es) 2021-10-04
BR112019015568B1 (pt) 2023-03-28
CN110325246B (zh) 2022-07-05
AU2018216043A1 (en) 2019-08-29
ES2981753T3 (es) 2024-10-10
CN110325246A (zh) 2019-10-11
BR112019015568A2 (pt) 2020-03-17
HUE053510T2 (hu) 2021-07-28
US20200100997A1 (en) 2020-04-02
HRP20210323T1 (hr) 2021-05-14
WO2018141988A1 (en) 2018-08-09
EP3725374B1 (en) 2024-06-19
EP3576846B1 (en) 2020-12-09
PT3576846T (pt) 2021-03-09

Similar Documents

Publication Publication Date Title
CY1123989T1 (el) Συνθεση αντηλιακου
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
CO2021008895A2 (es) Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2a
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
CY1120548T1 (el) Νανοσωματιδιο που περιλαμβανει ραπαμυκινη και αλβουμινη ως αντικαρκινικος παραγοντας
BR112019018093A2 (pt) Compostos, composição, método de inibição de hpk1, métodos para melhorar uma resposta imune e para tratar um distúrbio e usos do composto
CY1120503T1 (el) Συνθεσεις οι οποιες περιλαμβανουν ζολεδρονικο οξυ ή σχετικες ενωσεις για ανακουφιση φλεγμονωδους πονου και σχετικων παθησεων
CY1121450T1 (el) Θεραπεια συνδυασμου για θεραπεια καρκινου
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
CR20150217A (es) Inhibidores de histona demetilasas
CL2016000045A1 (es) Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cáncer.
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
CL2019003886A1 (es) Composiciones y métodos para modular el crecimiento del cabello.
PE20151594A1 (es) Inhibidores de indolamina 2-3 dioxigenasa
ECSP23007180A (es) Compuestos tricíclicos de urea como inhibidores de jak2 v617f
EA201591599A1 (ru) Ингибиторы ido
EA201690306A1 (ru) Ингибиторы ido
BR112018016054A2 (pt) composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
PE20151982A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
TR201902440T4 (tr) Alopesi tedavisine yönelik farmasötik ya da kozmetik bileşim.
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
EA201792304A1 (ru) Комбинированная терапия для лечения рака
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue